Advertisement

Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose

      Abstract

      Purpose

      The purpose of this study was to retrospectively evaluate symptoms, images of salivary gland dysfunction, and related clinical factors in thyroid cancer patients with total thyroidectomy followed by radioiodine therapy (RIT).

      Methods

      We included 164 patients who underwent thyroid ultrasonography or contrast-enhanced neck computed tomography more than 6 months later after RIT. Correlation between subjective symptoms and various RIT doses was also evaluated.

      Results

      Swelling and decreased salivary volume were the most common symptoms and images. RIT dose was the only factor with a positive correlation (P<.001).

      Conclusion

      The dose of RIT should be carefully determined to minimize gland dysfunction.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schlumberger MJ
        Papillary and follicular thyroid carcinoma.
        N Engl J Med. 1998; 338: 297-306
        • Schlumberger M
        • Catargi B
        • Borget I
        • Deandreis D
        • Zerdoud S
        • Bridji B
        • et al.
        Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
        N Engl J Med. 2012; 366: 1663-1673
        • Alexander C
        • Bader JB
        • Schaefer A
        • Finke C
        • Kirsch CM
        Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma.
        J Nucl Med. 1998; 39: 1551-1554
        • Helman J
        • Turner RJ
        • Fox PC
        • Baum BJ
        99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl− co-transport system.
        J Clin Invest. 1987; 79: 1310-1313
        • Newkirk KA
        • Ringel MD
        • Wartofsky L
        • Burman KD
        The role of radioactive iodine in salivary gland dysfunction.
        Ear Nose Throat J. 2000; 79: 460-468
        • Burke CJ
        • Thomas RH
        • Howlett D
        Imaging the major salivary glands.
        Br J Oral Maxillofac Surg. 2011; 49: 261-269
        • Mandel SJ
        • Mandel L
        Radioactive iodine and the salivary glands.
        Thyroid. 2003; 13: 265-271
        • Raza H
        • Khan AU
        • Hameed A
        • Khan A
        Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
        Nucl Med Commun. 2006; 27: 495-499
        • Caglar M
        • Tuncel M
        • Alpar R
        Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
        Clin Nucl Med. 2002; 27: 767-771
        • Solans R
        • Bosch JA
        • Galofre P
        • Porta F
        • Rosello J
        • Selva-O'Callagan A
        • et al.
        Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
        J Nucl Med. 2001; 42: 738-743
        • Fox PC
        Acquired salivary dysfunction. Drugs and radiation.
        Ann N Y Acad Sci. 1998; 842: 132-137
        • Jeong SY
        • Kim HW
        • Lee SW
        • Ahn BC
        • Lee J
        Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
        Thyroid. 2013; 23: 609-616
        • Almeida JP
        • Sanabria AE
        • Lima EN
        • Kowalski LP
        Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.
        Head Neck. 2011; 33: 686-690
        • Nabaa B
        • Takahashi K
        • Sasaki T
        • Okizaki A
        • Aburano T
        Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.
        AJNR. 2012; 33: 1964-1970
        • Freitas JE
        • Gross MD
        • Ripley S
        • Shapiro B
        Radionuclide diagnosis and therapy of thyroid cancer: current status report.
        Semin Nucl Med. 1985; 15: 106-131
        • Spiegel W
        • Reiners Chr
        • Börner W
        Sialadenitis following iodine-131 therapy for thyroid carcinoma.
        J Nucl Med. 1985; 26: 816-817
        • Nakada K
        • Ishibashi T
        • Takei T
        • Hirata K
        • Shinohara K
        • Katoh S
        • et al.
        Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?.
        J Nucl Med. 2005; 46: 261-266